EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action

Kevin Wilhelmsen iD, Aditi Deshpande iD, Sarah Tronnes iD, Maitriyee Mahanta iD, Matthew Banicki iD, Mary Cochran iD, Samantha Cowdin iD, Kristen Fortney iD, George Hartman iD, Robert E Hughes iD, Rusty Montgomery iD, Claudia P Portillo iD und 23 weitere

Journal of Experimental Medicine · 03.11.2025 · 222 (11)

DOI: 10.1084/jem.20242403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 02.09.2025. Verfasst von Kevin Wilhelmsen und 34 weiteren Autor:innen. Beteiligte Einrichtung: BioAge Labs , Emeryville, CA, USA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Drug Discovery. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Academy of Medical Sciences, Studienstiftung des deutschen Volkes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NLRP3 inflammasome is an intracellular protein complex that causes inflammation via the release of IL-1β and pyroptosis. NLRP3 activation is associated with many age-related inflammatory diseases, and NLRP3 inhibition is a promising therapeutic strategy. We previously performed a DNA-encoded library screen to identify novel NLRP3-binding molecules. Herein we describe the characterization of BAL-0028 as a potent and specific inhibitor of NLRP3 signaling. Notably, BAL-0028 is a poor inhibitor of mouse NLRP3 but inhibits human and primate NLRP3 with nanomolar potency. Using cellular and biochemical analyses, we demonstrate that BAL-0028 binds to the NLRP3 NACHT domain at a site that is distinct from the MCC950-binding pocket. Using humanized NLRP3 mice, we show that a derivative of BAL-0028, BAL-0598, inhibits NLRP3 activation in vivo in a peritonitis model. Finally, we demonstrate that both BAL-0028 and BAL-0598 inhibit select hyperactive NLRP3 mutations associated with autoinflammatory diseases more potently than MCC950. BAL-0028 and BAL-0598 thus represent a new modality for NLRP3 inhibition in inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinDrug DiscoveryHumansAnimalsMiceInflammasomesHEK293 CellsPeritonitisSignal TransductionMutationInterleukin-1beta

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLRP3 protein, humanInterleukin-1beta

Autor:innen und Institutionen

  • BioAge Labs , Emeryville, CA, USA.
  • HitGen Pharmaceuticals Inc. , Houston, TX, USA.
  • CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon , Lyon, France.
  • Institute of Structural Biology, University of Bonn , Bonn, Germany.
  • Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.
  • Department of Innate Immunity, Institute of Immunology, Tübingen, Germany.

ORCID-Profile: Kevin Wilhelmsen, Aditi Deshpande, Sarah Tronnes, Maitriyee Mahanta, Matthew Banicki, Mary Cochran, Samantha Cowdin, Kristen Fortney, George Hartman, Robert E Hughes, Rusty Montgomery, Claudia P Portillo, Paul Rubin, Taiz Salazar, Yan Wang, Shijun Yan, Barry A Morgan, Assem Duisembekova, Romane Riou, Michael Marleaux, Inga V Hochheiser, Hannes Buthmann, Dominic Ferber, Jane Torp, Wei Wang, Melanie Cranston, Chloe M McKee, Thea J Mawhinney, Emma C McKay, Fehime K Eroglu, Jasmin Kümmerle-Deschner, Alexander N R Weber, Bénédicte F Py, Matthias Geyer, Rebecca C Coll

Förderung

  • Biotechnology and Biological Sciences Research Council
  • Academy of Medical Sciences
  • Studienstiftung des deutschen Volkes
  • European Research Council
  • German Research Foundation
  • University of Tübingen
  • Baden-Württemberg Federal Ministry of Science, Research and Arts
  • French National Research Agency

Zitieren

APA

Wilhelmsen, K., Deshpande, A., Tronnes, S., Mahanta, M., Banicki, M., Cochran, M., Cowdin, S., Fortney, K., Hartman, G., Hughes, R. E., Montgomery, R., Portillo, C. P., Rubin, P., Salazar, T., Wang, Y., Yan, S., Morgan, B. A., Duisembekova, A., Riou, R., …, & Coll, R. C. (2025). Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action. Journal of Experimental Medicine, 222(11). https://doi.org/10.1084/jem.20242403

Vancouver

Wilhelmsen K, Deshpande A, Tronnes S, Mahanta M, Banicki M, Cochran M, et al. Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action. Journal of Experimental Medicine. 2025;222(11). doi:10.1084/jem.20242403

BibTeX
@article{Wilhelmsen2025,
  author = {Wilhelmsen, Kevin and Deshpande, Aditi and Tronnes, Sarah and Mahanta, Maitriyee and Banicki, Matthew and Cochran, Mary and Cowdin, Samantha and Fortney, Kristen and Hartman, George and Hughes, Robert E and Montgomery, Rusty and Portillo, Claudia P and Rubin, Paul and Salazar, Taiz and Wang, Yan and Yan, Shijun and Morgan, Barry A and Duisembekova, Assem and Riou, Romane and Marleaux, Michael and Hochheiser, Inga V and Buthmann, Hannes and Ferber, Dominic and Torp, Jane and Wang, Wei and Cranston, Melanie and McKee, Chloe M and Mawhinney, Thea J and McKay, Emma C and Eroglu, Fehime K and Kümmerle-Deschner, Jasmin and Weber, Alexander N R and Py, Bénédicte F and Geyer, Matthias and Coll, Rebecca C},
  title = {Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  volume = {222},
  number = {11},
  doi = {10.1084/jem.20242403}
}
Kostenlos starten →